Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 7340
IPSCIO Record ID: 7324
In return, the Licensee granted the Company an exclusive license to use Licensee's technology for certain applications.
The TUNA System is designed to offer a minimally invasive alternative for the treatment of benign prostatic hyperplasia by selectively shrinking the hyperplastic tissue that compresses the urethra limiting urinary flow.
IPSCIO Record ID: 25837
NX-1207 is an office-based pro-apoptotic protein injectable for BPH and for low grade localized prostate cancer. The drug mechanism of action is to lead to programmed natural cell death (apoptosis) selectively in prostate glands when injected intraprostatically by the transrectal route.
IPSCIO Record ID: 1617
IPSCIO Record ID: 238982
6,265,448 – Method for chemoprevention of prostate cancer
6,413,533 – Method for chemoprevention of prostate cancer
6,413,534 – Method for chemoprevention of prostate cancer
6,410,043 – Method for chemoprevention of prostate cancer
6,413,535 – Method for chemoprevention of prostate cancer
Licensed Technology shall mean any technology, trade secrets, methods, processes, know-how, show-how, data, information, or results relating to the patent applications, developed by the Contributors and owned by University, including the chemoprevention of prostate cancer and, more particularly, to a method of administering to a subject an effective dose of a chemopreventive agent or pharmaceutical preparation comprising an anti-estrogen or SERM, including, toremifene and analogs or metabolites thereof, to prevent recurrence of, suppress or inhibit prostate carcinogenesis.
IPSCIO Record ID: 328171
For the Licenses, Licensor grants throughout the territory, for the sole purpose of developing, making, having made, using and selling selective Alpha-1 an Adrenergic Receptor Products which are not BPH Products, a non-exclusive license under any of the Receptor patents. The section of the license grant shall extend back in time to apply to acts by Licensee prior to the Effective Date of this agreement.
Licensor grants, throughout the Territory, for the sole purpose of developing, making, having made and using but not selling BPH Products a nonexclusive license under the Receptor Patents.
Licensor grants, throughout the Territory, for the sole purpose of developing, making, having made and using but not selling BPH Products a nonexclusive license under the Functional Use Patents.
Upon exercise of the Option, Licensor grants throughout the Territory, for the sole purpose of developing, making, having made, using and selling BPH Products a non-exclusive license under the Patents.
BPH Compound shall mean any Selective Alpha-1a Adrenergic Receptor Compound for which regulatory approval to sell for the treatment of BPH or for the inhibition of contraction of prostate tissue has been obtained or is being sought.
BPH Product shall mean any prescription or over-the-counter pharmaceutical preparation containing BPH Compounds for use in humans.
Human Alpha-1 Adrenergic Receptors shall mean alpha-1a , alpha-1b, and, alpha-1d.
Selective Alpha-1 Adrenergic Receptor Product shall mean any prescription or over-the-counter pharmaceutical preparation containing Selective Alpha-1a Adrenergic Receptor Compounds for use in human or non-human animals.
The Therapeutic indication shall mean, with respect to any Selective Alpha-1a Adrenergic Receptor Product, the main therapeutic use as classified in the 2nd level of the World Health Organization Anatomical, Therapeutic, Clinical (ATC) drug classification system.
Licensee is developing selective human alpha-1a adrenergic receptor compounds which may be useful for the treatment of BPH and other medical conditions and is using cloned human alpha-1 adrenergic receptors.
IPSCIO Record ID: 29294
IPSCIO Record ID: 299258
Licensor grants an irrevocable, non-exclusive, worldwide right and license under the Licensed Patents only within the Technology Field to undertake Product Related Activities for Licensed Products and develop, make, have made, market, use, authorize others to use, import, distribute, sell, have sold and offer to sell Licensed Products, for the life of the Licensed Patents.
Licensed Products shall mean Licensees Current Products and Reasonable Modifications thereof developed, manufactured, used, marketed, offered for sale, sold, imported, licensed or distributed by or on behalf of a Licensee Party or a permitted successor or assign under this Agreement, directly or through their respective manufacturers, distributors, contractors, resellers, and other intermediaries.
Current Products of a Party shall mean products and components thereof commercially available from that Party or its Affiliates at or before the Effective Date in the Technology Field, which for Licensee is the Prolieve Thermodilation System and for Licensor is the TherMatrx System.
Prolieve Thermodilation System offers a unique â€œThermodilatationâ€ treatment for symptoms of enlarged prostate, also known as benign prostatic hyperplasia (BPH). ProlieveÂ® is a combination therapy simultaneously using Focused Microwave Heating together with Pressurized Balloon Dilatation therapy.
Technology Field shall mean the field of microwave therapy for treating benign prostatic hyperplasia (BPH) and prostatitis.
IPSCIO Record ID: 203339
The Fareston Product shall mean the Orion Product in 60 mg tablet form containing Toremifene that was promoted in the USA under the brand name Fareston by Shire prior to the Restatement Date for use in the Breast Cancer Field.
Toremifene shall mean [tore mi f ene citrate and/or the Z-isomer of 4-chloro-1, 2 diphenyl-1-(4-(2-(N,N-dimethylamino)-ethoxy) – phenyl]- 1 -butene].
IPSCIO Record ID: 203383
– a non-exclusive right and license, with the right to grant sublicenses, under Licensor Patent Rights and
Licensor Know-How, to develop, use, have used, sell, have sold, import, market and distribute the Product in the ROW Territory for exclusive use in the Field;
– a non-exclusive license, under the Licensor Patents and Know-How, to perform research and preclinical development activities using the Powder.
Toremifene' shall mean [toremifene citrate and/or 4-chloro-l, 2 diphenyl-1-(4(2-(N,N-dimethylamino)-ethoxyl) – phenyl] -I-butene].
Toremifene is a selective estrogen receptor modulator (SERM) of the triphenylethylene group related to tamoxifen which opposes the actions of estrogens like estradiol in the body and is approved for use in the treatment of advanced (metastatic) breast cancer.
IPSCIO Record ID: 344493
Licensor grants a right of first negotiation to Licensee in case Licensee intends to license from Licensor any additional analogs which all under a valid claim of the LHRH Patents in the United States.
The active ingredient is referred to as ozarelix. Ozarelix is a Luteinizing Hormone Releasing Hormone, or LHRH, antagonist (a substance that blocks the effects of a natural hormone found in the body). Mechanistically, LHRH antagonists exert rapid inhibition of luteinizing hormone and follicle stimulating hormone with an accompanying rapid decrease in sex hormones and would therefore be expected to be effective in a variety of hormonally dependent disease states including ovarian cancer, prostate cancer, BPH, infertility, uterine myoma and endometriosis.
LHRH Patents shall mean the composition in matter patents regarding a novel LHRH antagonist having improved solubility propertiesÂ· with the internal No. 98/20 PH, the LHRH.
The patents are titled
— LHRH antagonists having improved solubility properties,
— Administration form for pharmaceutically active peptides with sustained release of active ingredient, and method for the production thereof,
— Application of initial Doses of LHRH Analogues and Maintenance Doses of LHRH Antagonists for the Treatment of Hormone-dependent Cancers and Corresponding Pharmaceutical Kits, and,
— Use of LHRH Antagonists for intermittent Treatments.
IPSCIO Record ID: 28967
The Licensor hereby grants the Licensee a license to use the Trademarks solely in connection with the testing, marketing, distribution, import, export, use, offer to sell and sale of the Products in the Territory during the Term of this Agreement.
Catheter Kit means the single-use disposable components of the PROLIEVE System.
The Prolieve system provides a 45-minute in-office treatment that combines our microwave thermotherapy capability with a proprietary balloon compression technology to both heat the prostate and dilate the prostatic urethra. The purpose of the Prolieve system is to provide a relatively painless and effective alternative to drug therapy and certain types of surgical procedures to treat the symptoms of BPH.